AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04880512
Drug: SYHX 1901 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHX 1901, oral tablets, in fasted state
Trial: NCT04880512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, oral tablets, in fasted state
Trial: NCT05505214
Drug: Bacterial decolonization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT.
Trial: NCT05615012
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05615012
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05615012
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05354752
Drug: VC005 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC005 groups repeat administration for 7 days
Trial: NCT05354752
Drug: VC005 Placebo tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC005 placebo groups repeat administration for 7 days
Trial: NCT05201560
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients of this group will receive Fentanyl
Trial: NCT05887895
Drug: INS062 injection、INS068 injection、HR20014 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects.~INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects.~HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects.
Trial: NCT05847439
Drug: [14C]BMS-986419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05561530
Drug: ALG-125755
RxNorm normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single or multiple doses of ALG-125755
Trial: NCT05561530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single or multiple doses of placebo
Trial: NCT04995159
Drug: Single anti-platelet therapy
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Aspirin will be discontinued one year after surgery and clopidogrel will be continued until 5 years after surgery.
Trial: NCT04995159
Drug: Dual anti-platelet therapy
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Patients continue to take dual antiplatelet (DAPT) drugs, including aspirin and clopidogrel, for 2 more years; then aspirin will be used alone from the 4th year to the 5th year.
Trial: NCT03747328
Drug: ABI-009
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nanoparticle albumin bound sirolimus
Trial: NCT05738759
Drug: Epidural Anesthetic Cocktail
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The anesthetic cocktail, consists of triamcinolone 40 mg, marcaine 5 mg, and morphine 3 mg, is soaked in the gelfoam size 1x2 cm and applied on the epidura before removal of the endoscope.
Trial: NCT05738759
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is soaked with NSS in the gelfoam size 1x2 cm as well and applied on the epidura before removal of the endoscope.
Trial: NCT04780841
Drug: RDX013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RDX013 is an experimental drug that is a potassium secretagogue
Trial: NCT04780841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment that looks identical to experimental treatment
Trial: NCT00545207
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po monthly for 2 years
Trial: NCT04784910
Drug: DWP14012 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 20mg, tablet, orally, once daily for up to 24 weeks
Trial: NCT04784910
Drug: DWP14012 20mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 20mg placebo-matching tablet, orally, once daily for up to 24 weeks
Trial: NCT04072471
Drug: Zurampic®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-interventional study where patients are exposed to Zurampic® plus a xanthine oxidase inhibitor (allopurinol or febuxostat) during the normal course of clinical practice
Trial: NCT04072471
Drug: Control group: xanthine oxidase inhibitor monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-interventional study where patients are exposed to xanthine oxidase inhibitor monotherapy (allopurinol or febuxostat) during the normal course of clinical practice
Trial: NCT06366568
Drug: fluoride toothpaste containing 1450 ppm of MFP in a PCC base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: toothbrushing 2x a day for 2 minutes each time
Trial: NCT04823962
Drug: Placebo hydrogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo hydrogel
Trial: NCT06234007
Drug: Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety run-in phase: Fruquintinib 4mg/d, oral, once daily, continuous treatment for 2 weeks, 1 week off, q3w, 6 cycles; If the number of patients experiencing dose-limiting toxicity (DLT) was ≤1, the study would continue at that dose level. If the number of patients with DLTs was \>1, the dose of fruquintinib was decreased to 3mg/d, qd po, d1-14, q3w, and the dose expansion phase was continued；Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;~Dose expansion phase: Fruquintinib RP2D, qd po, d1-14, q3w, 6 cycles; Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;
Trial: NCT05606497
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal corticosteroids are administered to pregnancies at risk for preterm birth in order to reduce risks of neonatal morbidity and mortality following preterm birth.
Trial: NCT04920916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline.
Trial: NCT04724044
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets of 500mg of clarithromycin
Trial: NCT00006235
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06136754
Drug: Varnishes, Fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish containing 5.0% NaF
Trial: NCT05476107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or daily dosing at doses A, B, C, D, E, F; G,H, and I
Trial: NCT05226559
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacological treatment alone.
Trial: NCT05217706
Drug: normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group will receive normal saline IV in a matched syringe
Trial: NCT04874675
Drug: ibuprofen/acetaminophen/codeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: routine pain medication used post extraction of third molars
Trial: NCT05028049
Drug: Sufentanil injection
RxNorm normalized name: sufentanil Injection
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia
Trial: NCT05028049
Drug: Remifentanil Hydrochloride
RxNorm normalized name: Remifentanil Hydrochloride
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia
Trial: NCT04727437
Drug: direct oral anticoagulants
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anticoagulation drug given for at least 3 months.
Trial: NCT04727437
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anticoagulation drug, subcutaneous injection given for at least 3 months.
Trial: NCT05569941
Drug: ABI-4334 Tablet
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABI-4334 Tablet
Trial: NCT05569941
Drug: ABI-4334 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to ABI-4334 Tablet
Trial: NCT06484634
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.
Trial: NCT06531369
Drug: Saline（C group）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil Injection（F2 group）: Immediately after surgery, an equal volume of saline (equal to the volume of 0.5 mg flumazenil) was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.
Trial: NCT05701644
Drug: C1K 150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administrate C1K 150mg at Day 1, Day 8, Day 15
Trial: NCT05701644
Drug: C1K 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administrate C1K 300mg at Day 1, Day 8, Day 15
Trial: NCT05701644
Drug: C1K 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administrate C1K 600mg at Day 1, Day 8, Day 15
Trial: NCT05701644
Drug: C1K 900mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administrate C1K 900mg at Day 1, Day 8, Day 15
Trial: NCT05701644
Drug: C1K 1200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administrate C1K 1200mg at Day 1, Day 8, Day 15
Trial: NCT00017160
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05596721
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treat patient with azithromycin for 12w.
Trial: NCT05596721
Drug: ICS/LABA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat patient with ICS/LABA according to Global Initiative for Asthma (GINA) guideline.
Trial: NCT06237491
Drug: 177Lu-LNC1003 Injection group 1
RxNorm normalized name: meningococcal group B vaccine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment regimen will consist of a single dose 30 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
Trial: NCT06237491
Drug: 177Lu-LNC1003 Injection group 2
RxNorm normalized name: meningococcal group B vaccine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment regimen will consist of a single dose 50 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
Trial: NCT06237491
Drug: 177Lu-LNC1003 Injection group 3
RxNorm normalized name: meningococcal group B vaccine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment regimen will consist of a single dose 70 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
Trial: NCT05865080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT04979273
Drug: Adrenaline 1 Mg/mL Solution for Injection
RxNorm normalized name: Adrenaline 1 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip
Trial: NCT06391164
Drug: XC243 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the Investigated Product (IP) once in the morning at least 30 minutes before eating for 7-10 days
Trial: NCT06391164
Drug: XC243 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
Trial: NCT06391164
Drug: XC243 75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
Trial: NCT06391164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
Trial: NCT05993143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Round and white tablets
Trial: NCT05061017
Drug: Cyclophosphamide (low dose)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is approved by the FDA for the treatment of acute lymphoblastic leukemia, acute monocytic leukemia, acute myeloid leukemia, breast cancer, chronic granulocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin lymphoma, multiple myeloma, mycosis fungoides, neuroblastoma, non-Hodgkin lymphoma, ovarian cancer, retinoblastoma. Low-dose (immunomodulatory) cyclophosphamide is being studied in combination with various types of immunotherapy including nivolumab and pembrolizumab
Trial: NCT06151496
Drug: Alpha-Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Trial: NCT06151496
Drug: α-adrenergic receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Trial: NCT05194878
Drug: neoadjuvant chemotherapyI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOXIRI (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV Irinotecan 150 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 48h every 14 days) for 6 cycles followed by colectomy (3 to 6 weeks after) . If PD was observed after 3 cycles, direct colectomy was performed.
Trial: NCT05194878
Drug: adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) . CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) . Oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days. The plan and cycles are determined according to the surgical pathology and physical conditions.
Trial: NCT05494918
Drug: JSKN003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JSKN003 is to be administered via intravenous (IV) dose
Trial: NCT05372783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluent solution
Trial: NCT06412588
Drug: Vonoprazan+amoxicillin+doxycycline+bismuth for 14 days
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Group A:The patient was treated with oral Vonoprazan 20 mg, bid + amoxicillin 1.0 g, bid + doxycycline 0.1 g, bid + bismuth for 14 days.
Trial: NCT06412588
Drug: Vonoprazan+doxycycline
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Group C: Patients were treated with oral Vonoprazan 20 mg, bid + doxycycline 0.1 g, bid for 14 days.
Trial: NCT06606899
Drug: Melatonin 3 MG
RxNorm normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral syrup melatonin 3 mg
Trial: NCT05438498
Drug: Evusheld (tixagevimab+cilgavimab) IM or IV
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evusheld (tixagevimab 300 mg +cilgavimab 300 mg) IM or IV
Trial: NCT05142098
Drug: Etoricoxib 60 mg
RxNorm normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally
Trial: NCT05033912
Drug: CST-2032, matching placebo for CST-2032, CST-107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CST-2032 and matching placebo oral liquid; CST-107 white capsules
Trial: NCT05426304
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 25 mg/day for 180 days
Trial: NCT04970108
Drug: Egito
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EGITO Egito coated tablet. EMPAGLIFLOZIN PLACEBO Empagliflozin placebo coated tablet. TELMISARTAN PLACEBO Telmisartan coated tablet.
Trial: NCT05791682
Drug: Sealant, Fissure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FISSURIT FX- MICROFILLED RESIN SEALANT WITH 55% FILLER GRANDIOSEAL- NANOFILLED RESIN SEALANT WITH 70% FILLER TE-ECONOM- FLOW -FLOWABLE COMPOSITE AS SEALANT CLINPRO TM- UNFILLED RESIN SEALANT
Trial: NCT05979363
Drug: VRD-based regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib, Lenalidomide and Dexamethasone
Trial: NCT04746911
Drug: ARQ-151 cream 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
Trial: NCT04753177
Drug: Doxorubicin, cyclophosphamide, paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
Trial: NCT04674748
Drug: INCB086550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each Participant will be treated at the specified dose level with a minimum of 3 subjects at each dose level. After the RP2D of INCB086550 is identified, the dose level will be expanded to better characterize the safety and tolerability and PK.
Trial: NCT04301284
Drug: CAD-1883
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg filled capsules
Trial: NCT04301284
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules
Trial: NCT04972123
Drug: CPC - Capsaicin, Phenylephrine, Caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPC is a combination of Capsaicin, Phenylephrine and Caffeine
Trial: NCT04972123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for CPC
Trial: NCT05114837
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 500 mg/m\^2 is administered as an IV infusion per institutional guidelines once a day on 2 consecutive days (Day -5, and Day -4)
Trial: NCT05167604
Drug: Adjuvants, Pharmaceutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with stage IB-IIA NSCLC after curative surgery were treated with adjuvant chemotherapy. The blood samples of the patients before and after adjuvant chemotherapy will be collected to examine the MRD status
Trial: NCT06532942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo across Part A and Part B of the study.
Trial: NCT04719507
Drug: Pethidine Only Product in Parenteral Dose Form
RxNorm normalized name: Pethidine only product in parenteral dose form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pethidine (1 mg/kg ) once
Trial: NCT05351554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously to match namilumab dosing
Trial: NCT04784754
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin capsules will be prepared using hypromellose capsules containing 3 mg or 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
Trial: NCT04784754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.
Trial: NCT05483595
Drug: Chinese herbal medicine FYTF-919
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liquid 10ml
Trial: NCT05056883
Drug: K-237 0.3-0.4mg/kg (once daily)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 3mg tablet
Trial: NCT05056883
Drug: Placebo 0.3-0.4mg/kg (once daily)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3mg tablet
Trial: NCT05927272
Drug: Systemic Steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral minipuls of systemic steroids (Medrol 16mg twice a week) for 24 weeks